ClinicalTrials.Veeva

Menu
T

TOI Clinical Research | TOI Clinical Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

MRTX849
Dexamethasone
Ritonavir
Docetaxel
Estrogen
MeziKD
Ibrutinib
Pirtobrutinib
Bevacizumab
Itraconazole

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 13 total trials

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced sol...

Enrolling
HER2-positive Advanced Solid Tumor
Drug: Itraconazole
Drug: Ritonavir

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Enrolling
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Fulvestrant
Drug: Dexamethasone Mouth Rinse

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants...

Active, not recruiting
Myelofibrosis (MF)
Drug: Navitoclax
Drug: Ruxolitinib
Locations recently updated

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Enrolling
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Drug: 5-Fluorouracil
Drug: Tislelizumab

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatmen...

Enrolling
Solid Tumor
APC Gene Mutation
Drug: REC-4881

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Mezigdomide
Drug: Dexamethasone

This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in...

Active, not recruiting
Non-Small Cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Drug: efineptakin alfa
Drug: Atezolizumab

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patien...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Adagrasib

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...

Active, not recruiting
Advanced Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Drug: Docetaxel
Drug: MRTX849

This trial will include 2 portions (phase 1 and phase 2).The first portion will be a Phase I, open label, dose escalation study to establish the maxi...

Active, not recruiting
Pancreatic Cancer
Biological: XB2001 or Placebo

Trial sponsors

Mirati Therapeutics logo
AbbVie logo
BeiGene logo
Bristol-Myers Squibb (BMS) logo
D
Genentech logo
Jazz Pharmaceuticals logo
Loxo Oncology logo
N
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems